Keryx: Panel says drug candidate doesn't raise safety concerns
Dec 6 (Reuters) - Keryx Biopharmaceuticals (KERX.O: Quote, Profile, Research, Stock Buzz) said an independent data safety monitoring committee (DSMC) found no safety concerns regarding Keryx's lead drug candidate, Sulonex, for the treatment of diabetic nephropathy.
The company said the DSMC had found no reason to recommend alteration or termination of the late-stage trial. The main goal of the late-stage trial is "therapeutic success" at six months.
Diabetic nephropathy is a complication of diabetes in which the kidneys are progressively damaged. (Reporting by Neha Pathania in Bangalore; Editing by Amitha Rajan)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Cash injection
Panic grips Asian investors